Pharmacokinetics and Bioequivalence of Tamsulosin Hydrochloride Extended‐Release Capsules in Healthy Chinese Volunteers: A Randomized, Open‐Label, Crossover Study Under Fasting and Fed Conditions
Clinical Pharmacology in Drug Development · 2026-07 · 15 (7)
DOI: 10.1002/cpdd.70078 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 20.07.2026. Verfasst von Lijie Du und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Hubei University of Science and Technology, Xianning, China. Hauptthemen laut MEDLINE: Adrenergic alpha-1 Receptor Antagonists, Fasting, Tamsulosin. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Shanghai Huiyong Pharmaceutical Co., Ltd.
Abstract (Originalsprache)
Tamsulosin hydrochloride is a long‐acting, highly selective α1A receptor antagonist, primarily used to treat benign prostatic hyperplasia. It effectively alleviates lower urinary tract symptoms, including dysuria, nocturia, and urgency caused by prostate enlargement. This study aimed to evaluate the pharmacokinetics and bioequivalence of two tamsulosin extended‐release capsules in Chinese volunteers under both fasting and fed conditions. A single‐center, randomized, open‐label, two‐formulation, single‐dose, two‐period, two‐way crossover design was used. A total of 64 healthy volunteers were enrolled, with 28 in the fasting group and 36 in the fed group. In the fasting group, each subject received a single dose of either the test or reference formulation in a randomized crossover design. In the fed group, volunteers consumed a high‐fat meal 1 h before dosing. Blood samples were collected for up to 72 h post‐dose, and plasma tamsulosin concentrations were measured using liquid chromatography‐tandem mass spectrometry. The geometric mean ratios and 90% confidence intervals for key exposure metrics for both formulations under fasting and fed conditions were within the 0.8000‐1.2500 bioequivalence range. Both formulations demonstrated bioequivalence under both conditions, and no severe adverse events were observed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Hubei University of Science and Technology, Xianning, China.
- Phase I Clinical Research Center, Xianning Central Hospital, The First Affiliated Hospital of Hubei University of Science and Technology, Xianning, China.
- Department of Neurosurgery, Xianning Central Hospital, The First Affiliated Hospital of Hubei University of Science and Technology, Xianning, China.
Förderung
- Shanghai Huiyong Pharmaceutical Co., Ltd
Zitieren
APA
Du, L., Wang, X., Zhang, Y., Yang, J., Gan, F., & Pang, Y. (2026). Pharmacokinetics and Bioequivalence of Tamsulosin Hydrochloride Extended‐Release Capsules in Healthy Chinese Volunteers: A Randomized, Open‐Label, Crossover Study Under Fasting and Fed Conditions. Clinical Pharmacology in Drug Development, 15(7). https://doi.org/10.1002/cpdd.70078
Vancouver
Du L, Wang X, Zhang Y, Yang J, Gan F, Pang Y. Pharmacokinetics and Bioequivalence of Tamsulosin Hydrochloride Extended‐Release Capsules in Healthy Chinese Volunteers: A Randomized, Open‐Label, Crossover Study Under Fasting and Fed Conditions. Clinical Pharmacology in Drug Development. 2026;15(7). doi:10.1002/cpdd.70078
BibTeX
@article{Du2026,
author = {Du, Lijie and Wang, Xiaolu and Zhang, Yi and Yang, Jiamin and Gan, Fangliang and Pang, Yaxun},
title = {Pharmacokinetics and Bioequivalence of Tamsulosin Hydrochloride Extended‐Release Capsules in Healthy Chinese Volunteers: A Randomized, Open‐Label, Crossover Study Under Fasting and Fed Conditions},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
volume = {15},
number = {7},
doi = {10.1002/cpdd.70078}
}
EUVIMED